Mineralocorticoid Receptor Antagonist Use in Hospitalized Patients with Heart Failure, Reduced Ejection Fraction, and Diabetes Mellitus (from the EVEREST Trial)

Despite the well-established benefits of mineralocorticoid receptor agonists (MRAs) in heart failure with reduced ejection fraction, safety concerns remain in patients with concomitant diabetes mellitus (DM) because of common renal and electrolyte abnormalities in this population. We analyzed all-ca...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Vaduganathan, Muthiah, Cas, Alessandra Dei, Mentz, Robert J., Greene, Stephen J., Khan, Sadiya, Subacius, Haris P., Chioncel, Ovidiu, Maggioni, Aldo P., Konstam, Marvin A., Senni, Michele, Fonarow, Gregg C., Butler, Javed, Gheorghiade, Mihai
Médium: Artigo
Jazyk:Inglês
Vydáno: 2014
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4160659/
https://ncbi.nlm.nih.gov/pubmed/25060414
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.amjcard.2014.05.064
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky